Literature DB >> 19191304

Current hypotheses for the underlying biology of amyotrophic lateral sclerosis.

Jeffrey D Rothstein1.   

Abstract

The mechanisms involved in selective motor neuron degeneration in amyotrophic lateral sclerosis remain unknown more than 135 years after the disease was first described. Although most cases have no known cause, mutations in the gene encoding Cu/Zn superoxide dismutase (SOD1) have been implicated in a fraction of familial cases of the disease. Transgenic mouse models with mutations in the SOD1 gene and other ALS genes develop pathology reminiscent of the disorder, including progressive death of motor neurons, and have provided insight into the pathogenesis of the disease but have consistently failed to predict therapeutic efficacy in humans. However, emerging research has demonstrated that mutations and pathology associated with the TDP-43 gene and protein may be more common than SOD1 mutations in familial and sporadic ALS. Putative mechanisms of toxicity targeting motor neurons include oxidative damage, accumulation of intracellular aggregates, mitochondrial dysfunction, defects in axonal transport, growth factor deficiency, aberrant RNA metabolism, glial cell pathology, and glutamate excitotoxicity. Convergence of these pathways is likely to mediate disease onset and progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19191304     DOI: 10.1002/ana.21543

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  271 in total

1.  Evaluation of occupational exposure to magnetic fields and motor neuron disease mortality in a population-based cohort.

Authors:  Lauren E Parlett; Joseph D Bowman; Edwin van Wijngaarden
Journal:  J Occup Environ Med       Date:  2011-12       Impact factor: 2.162

2.  Advances in the application of MRI to amyotrophic lateral sclerosis.

Authors:  Martin R Turner; Michel Modo
Journal:  Expert Opin Med Diagn       Date:  2010-11

3.  Immunocytochemical localization of TASK-3 channels in rat motor neurons.

Authors:  Christiane Marinc; Harald Prüss; Christian Derst; Rüdiger W Veh
Journal:  Cell Mol Neurobiol       Date:  2011-10-20       Impact factor: 5.046

Review 4.  How can we improve clinical trials in amyotrophic lateral sclerosis?

Authors:  Paul H Gordon; Vincent Meininger
Journal:  Nat Rev Neurol       Date:  2011-09-27       Impact factor: 42.937

Review 5.  Import, maturation, and function of SOD1 and its copper chaperone CCS in the mitochondrial intermembrane space.

Authors:  Hibiki Kawamata; Giovanni Manfredi
Journal:  Antioxid Redox Signal       Date:  2010-11-01       Impact factor: 8.401

6.  Blocking IL-1beta to slow down progression of ALS?

Authors:  Jos W M van der Meer; Anna Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

7.  ALS-linked mutant superoxide dismutase 1 (SOD1) alters mitochondrial protein composition and decreases protein import.

Authors:  Quan Li; Christine Vande Velde; Adrian Israelson; Jing Xie; Aaron O Bailey; Meng-Qui Dong; Seung-Joo Chun; Tamal Roy; Leah Winer; John R Yates; Roderick A Capaldi; Don W Cleveland; Timothy M Miller
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

8.  Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis.

Authors:  Radhia Benmohamed; Anthony C Arvanites; Jinho Kim; Robert J Ferrante; Richard B Silverman; Richard I Morimoto; Donald R Kirsch
Journal:  Amyotroph Lateral Scler       Date:  2010-11-12

9.  Immunological aspects in amyotrophic lateral sclerosis.

Authors:  Maria Carolina O Rodrigues; Júlio C Voltarelli; Paul R Sanberg; Cesario V Borlongan; Svitlana Garbuzova-Davis
Journal:  Transl Stroke Res       Date:  2012-05-03       Impact factor: 6.829

10.  Effects of Tongue Force Training on Bulbar Motor Function in the Female SOD1-G93A Rat Model of Amyotrophic Lateral Sclerosis.

Authors:  Delin Ma; Jeffrey M Shuler; Aishwarya Kumar; Quincy R Stanford; Sudheer Tungtur; Hiroshi Nishimune; John A Stanford
Journal:  Neurorehabil Neural Repair       Date:  2016-09-24       Impact factor: 3.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.